Epistem Seeks to Raise $6.7M as it Prepares to Launch MDx Instrument | GenomeWeb

NEW YORK (GenomeWeb News) – UK firm Epistem today announced its intention to raise £4.2 million ($6.7 million) in net proceeds in preparation of the launch of its molecular diagnostics platform and a tuberculosis assay.

The company will place 793,398 new ordinary shares of its stock at 1.5 pence each with new and existing investors. The shares have been conditionally placed at a price of 545 pence per share, a 4 percent discount to Epistem's closing price on Dec. 6, the company said.

Peel Hunt is underwriting the placement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.